Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body 18F-FDG PET/CT scans

Dias, André H.; Pedersen, Mette F.; Danielsen, Helle; Munk, Ole Lajord; Gormsen, Lars Christian

doi:10.1007/s00259-020-05007-2

Cited by 50 publications

(64 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, tumor MR FDG values from a large cohort including 11 different cell line tumors were in the same range as ours (30). Interestingly, a recent dynamic 18 F-FDG-PET study including 101 patients diagnosed with a range of cancers, demonstrated clinical feasibility and superior quanti cation using MR FDG with higher tumor-to-background-and contrast-to-noise ratios compared to conventional tumor SUV values (19). Interestingly, they reported a signi cant positive correlation between K i (which is directly derived from MR FDG ) and SUV mean , which is in line with our nding.…”

Section: Discussionsupporting

confidence: 59%

“…Interestingly, a recent study using a dynamic 18 F-FDG-PET-CT protocol demonstrated the clinical feasibility and superior performance of the dynamic imaging parameter, metabolic rate of 18 F-FDG (MR FDG ), compared to the static imaging parameters; i.e. standardized uptake values (SUV) in 101 patients diagnosed with cancers from different origins (19). Preclinical use of standard clinical imaging methods in endometrial cancer (EC) is currently limited.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility and Utility of MRI and Dynamic 18F-FDG-PET in An Orthotopic Organoid-Based Patient-Derived Mouse Model of Endometrial Cancer

Espedal

Berg

Fonnes

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Pelvic magnetic resonance imaging (MRI) and whole-body positron emission tomography-computed tomography (PET-CT) play an important role at primary diagnostic work-up and in detecting recurrent disease in endometrial cancer (EC) patients, however the preclinical use of these imaging methods is currently limited. We demonstrate the feasibility and utility of MRI and dynamic 18F-fluorodeoxyglucoce (FDG)-PET imaging for monitoring tumor progression and assessing chemotherapy response in an orthotopic organoid-based patient-derived xenograft (O-PDX) mouse model of EC.Methods: 19 O-PDX mice (grade 3 endometrioid EC, stage IIIC1), selectively underwent weekly T2-weighted MRI (total scans=32), diffusion-weighted MRI (DWI) (total scans=9) and dynamic 18F-FDG-PET (total scans=26) during tumor progression. MRI tumor volumes (vMRI), tumor apparent diffusion coefficient values (ADCmean) and metabolic tumor parameters from 18F-FDG-PET including maximum and mean standard uptake values (SUVmax/SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and metabolic rate of 18F-FDG (MRFDG) were calculated. Correlation between imaging parameters was assessed using a two-tailed Spearman test. Further, nine mice were included in a chemotherapy treatment study (treatment; n=5, controls; n=4) and tumor ADCmean-values were compared to changes in vMRI and cellular density from histology at endpoint. A Mann-Whitney test was used to evaluate differences between groups. Results: Tumors with large tumor volumes (vMRI) had significantly higher metabolic activity (MTV and TLG; r=0.93, p<0.0001). Non-invasive calculation of MRFDG from dynamic 18F-FDG-PET (mean MRFDG=0.39 mmol/min) was feasible using an image-derived input function. Treated mice had higher tumor ADCmean (p=0.03) and lower vMRI (p=0.03) and tumor cellular density (p=0.02) than non-treated mice, all indicating treatment response.Conclusion: Preclinical imaging mirroring clinical imaging methods in EC is highly feasible for monitoring tumor progression and treatment response in the present orthotopic organoid mouse model.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Feasibility and Utility of MRI and Dynamic 18F-FDG-PET in An Orthotopic Organoid-Based Patient-Derived Mouse Model of Endometrial Cancer

Espedal

Berg

Fonnes

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…K i parametric imaging seems to be particularly valuable to differentiate abnormal uptake lesions with gradual increase in FDG uptake from physiological uptake areas with gradual decrease in uptake such as liver and vessels. K i may reflect count change, and, therefore, has a potential to enhance detection of abnormal FDG uptake lesions in high background areas [48,49].…”

Section: Discussionmentioning

confidence: 99%

Dynamic whole-body FDG-PET imaging for oncology studies

Tamaki

Kotani

Nishimura

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

Introduction Recent PET/CT systems have improved sensitivity and spatial resolution by smaller PET detectors and improved reconstruction software. In addition, continuous-bed-motion mode is now available in some PET systems for whole-body PET imaging. In this review, we describe the advantages of dynamic whole-body FDG-PET in oncology studies. Methods PET–CT imaging was obtained at 60 min after FDG administration. Dynamic whole-body imaging with continuous bed motion in 3 min each with flow motion was obtained over 400 oncology cases. For routine image analysis, these dynamic phases (usually four phases) were summed as early FDG imaging. The image quality of each serial dynamic imaging was visually evaluated. In addition, changes in FDG uptake were analyzed in consecutive dynamic imaging and also in early delayed (90 min after FDG administration) time point imaging (dual-time-point imaging; DTPI). Image interpretation was performed by consensus of two nuclear medicine physicians. Result All consecutive dynamic whole-body PET images of 3 min duration had acceptable image quality. Many of the areas with physiologically high FDG uptake had altered uptake on serial images. On the other hand, most of the benign and malignant lesions did not show visual changes on serial images. In the study of 60 patients with suspected colorectal cancer, unchanged uptake was noted in almost all regions with pathologically proved FDG uptake, indicating high sensitivity with high negative predictive value on both serial dynamic imaging and on DTPI. We proposed another application of serial dynamic imaging for minimizing motion artifacts for patients who may be likely to move during PET studies. Discussion Dynamic whole-body imaging has several advantages over the static imaging. Serial assessment of changes in FDG uptake over a short period of time is useful for distinguishing pathological from physiological uptake, especially in the abdominal regions. These dynamic PET studies may minimize the need for DPTI. In addition, continuous dynamic imaging has the potential to reduce motion artifacts in patients who are likely to move during PET imaging. Furthermore, kinetic analysis of the FDG distribution in tumor areas has a potential for precise tissue characterization. Conclusion Dynamic whole-body FDG-PET imaging permits assessment of serial FDG uptake change which is particularly useful for differentiation of pathological uptake from physiological uptake with high diagnostic accuracy. This imaging can be applied for minimizing motion artifacts. Wide clinical applications of such serial, dynamic whole-body PET imaging is expected in oncological studies in the near future.

show abstract

“…Moreover, tumor MR FDG values from a large cohort including 11 different cell line tumors were in the same range as ours [ 32 ]. Interestingly, a recent dynamic 18 F-FDG-PET study including 101 patients diagnosed with a range of cancers, demonstrated clinical feasibility and superior quantification using MR FDG with higher tumor-to-background- and contrast-to-noise ratios compared to conventional tumor SUV values [ 20 ]. Interestingly, they reported a significant positive correlation between K i (which is directly derived from MR FDG ) and SUV mean , which is in line with our finding.…”

Section: Discussionmentioning

confidence: 99%

“…Primary ECs are typically highly 18 F-FDG avid [ 18 ]. Interestingly, a recent study using a dynamic 18 F-FDG-PET-CT protocol demonstrated the clinical feasibility and superior performance of the dynamic imaging parameter, metabolic rate of 18 F-FDG (MR FDG ), compared to the static imaging parameters; i.e., standardized uptake values (SUV) in 101 patients diagnosed with cancers from different origins [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer

et al. 2021

View full text Add to dashboard Cite

Background Pelvic magnetic resonance imaging (MRI) and whole-body positron emission tomography-computed tomography (PET-CT) play an important role at primary diagnostic work-up and in detecting recurrent disease in endometrial cancer (EC) patients, however the preclinical use of these imaging methods is currently limited. We demonstrate the feasibility and utility of MRI and dynamic 18F-fluorodeoxyglucose (FDG)-PET imaging for monitoring tumor progression and assessing chemotherapy response in an orthotopic organoid-based patient-derived xenograft (O-PDX) mouse model of EC. Methods 18 O-PDX mice (grade 3 endometrioid EC, stage IIIC1), selectively underwent weekly T2-weighted MRI (total scans = 32), diffusion-weighted MRI (DWI) (total scans = 9) and dynamic 18F-FDG-PET (total scans = 26) during tumor progression. MRI tumor volumes (vMRI), tumor apparent diffusion coefficient values (ADCmean) and metabolic tumor parameters from 18F-FDG-PET including maximum and mean standard uptake values (SUVmax/SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and metabolic rate of 18F-FDG (MRFDG) were calculated. Further, nine mice were included in a chemotherapy treatment study (treatment; n = 5, controls; n = 4) and tumor ADCmean-values were compared to changes in vMRI and cellular density from histology at endpoint. A Mann–Whitney test was used to evaluate differences between groups. Results Tumors with large tumor volumes (vMRI) had higher metabolic activity (MTV and TLG) in a clear linear relationship (r2 = 0.92 and 0.89, respectively). Non-invasive calculation of MRFDG from dynamic 18F-FDG-PET (mean MRFDG = 0.39 μmol/min) was feasible using an image-derived input function. Treated mice had higher tumor ADCmean (p = 0.03), lower vMRI (p = 0.03) and tumor cellular density (p = 0.02) than non-treated mice, all indicating treatment response. Conclusion Preclinical imaging mirroring clinical imaging methods in EC is highly feasible for monitoring tumor progression and treatment response in the present orthotopic organoid mouse model.

show abstract

Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body 18F-FDG PET/CT scans

Cited by 50 publications

References 21 publications

Feasibility and Utility of MRI and Dynamic 18F-FDG-PET in An Orthotopic Organoid-Based Patient-Derived Mouse Model of Endometrial Cancer

Feasibility and Utility of MRI and Dynamic 18F-FDG-PET in An Orthotopic Organoid-Based Patient-Derived Mouse Model of Endometrial Cancer

Dynamic whole-body FDG-PET imaging for oncology studies

Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer

Contact Info

Product

Resources

About